Fate Therapeutics (FATE) Accounts Payables (2012 - 2026)

Fate Therapeutics has reported Accounts Payables for 15 years, with the latest figure at $3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 21.79% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $3.3 million (down 21.79% YoY), and the FY2025 full-year result was $2.7 million, down 71.64% from the prior year.
• Accounts Payables for Q1 2026 stood at $3.3 million, up from $2.7 million in the prior quarter.
• The five-year high for Accounts Payables was $11.4 million in Q1 2022, with the low at $2.7 million in Q4 2025.
• Historically, Accounts Payables has averaged $6.5 million across 5 years, with a median of $6.3 million in 2024.
• Annual changes were most pronounced in 2024 — Accounts Payables surged 98.45% — and 2025, when it plunged 71.64%.
• Fate Therapeutics' Accounts Payables stood at $8.3 million in 2022, then slumped by 42.9% to $4.7 million in 2023, then soared by 98.45% to $9.4 million in 2024, then sank by 71.64% to $2.7 million in 2025, then advanced by 23.38% to $3.3 million in 2026.
• The last three Accounts Payables figures came in at $3.3 million (Q1 2026), $2.7 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.